セフピラミド
セフピラミド 物理性質
- 融点 :
- 213-215° (dec)
- 比重(密度) :
- 1.75±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- -20°C Freezer, Under Inert Atmosphere
- 溶解性:
- DMSO（微量）、メタノール（微量）
- 外見 :
- 個体
- 酸解離定数(Pka):
- 2.62±0.50(Predicted)
- 色:
- 白い
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01USP1098118 |
セフピラミド
Cefpiramide |
70797-11-4 |
300mg |
￥73500 |
2021-03-23 |
購入 |
セフピラミド 化学特性,用途語,生産方法
効能
抗生物質, 細胞壁合成阻害薬
使用
Antibacterial.
定義
ChEBI: A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectiv
ly, of the cephem skeleton. It has a broad spectrum of antibacterial activity.
抗菌性
A semisynthetic parenteral cephalosporin. It exhibits a broad
range of activity, which includes Ps. aeruginosa, though the overall activity is rather modest. It is moderately
stable to most β-lactamases but less so than ceftazidime or
cefpirome.
In volunteers given 0.5 or 1 g by intravenous bolus, the mean
plasma concentration shortly after injection was around 150 or
300 mg/L, respectively. There was no accumulation when the
same doses were repeated every 12 h for 11 doses. It is highly
bound to plasma protein (c. 95%). The mean plasma half-life
is around 5 h. Less than one-quarter of the dose appears in the
urine over 24 h; the rest is excreted in bile and high concentrations
are found in feces. Renal impairment has little effect on
elimination in patients with normal liver function.
Diarrhea may be associated with marked suppression of
gut flora resulting from biliary excretion of the drug. The molecule
includes a C-3 methylthiotetrazole side chain and side
effects associated with that substituent are to be expected.
It is available in Japan.
セフピラミド 上流と下流の製品情報
原材料
準備製品
セフピラミド 生産企業
Global( 155)Suppliers
70797-11-4(セフピラミド)キーワード:
- 70797-11-4
- (6R,7R)-7-[(2R)-2-(4-hydroxyphenyl)-2-[(6-Methyl-4-oxo-1,4-dihydropyridin-3-yl)forMaMido]acetaMido]-3-{[(1-Methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]Methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 7-aMino-3-(1-Methyl-1-pyrroleane oniuM acids)Methyl-2-oxacepheMs-2-Carboxylic Acid Hydrochloride
- Suncefal：Sepatren
- 7-[2-[(4-hydroxy-6-methylpyridine-3-carbonyl)-amino]-2-(4-hydroxy phenyl)-acetylamin]-3-(1-methyl-1h-tetrazole-5-thiomethyl)-8-keto-5-thiox-1-azole[4.2.0]octadiene-2-carboxylic acid
- CEFPIRAMIDE
- cefpiramide acid
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,7β(R*)]]-
- Cefpiramide (300 mg)
- sodium 7-[[2-(4-hydroxyphenyl)-2-[[(6-methyl-4-oxo-1H-pyridin-3-yl)-oxomethyl]amino]-1-oxoethyl]amino]-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- Cefpiramido
- Cefpiramidum
- 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-
- Cefpiramide acid USP/EP/BP
- Cefpiramide (1098118)
- (6R,7R)-7-((R)-2-(4-hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- セフピラミド
- (6R,7R)-7α-[[(R)-[[[4-ヒドロキシ-6-メチル-3-ピリジニル]カルボニル]アミノ](4-ヒドロキシフェニル)アセチル]アミノ]-3-[[(1-メチル-1H-テトラゾール-5-イル)チオ]メチル]-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- (6R,7R)-7-[(2R)-2-[(4-ヒドロキシ-6-メチルピリジン-3-イル)ホルムアミド]-2-(4-ヒドロキシフェニル)アセトアミド]-3-{[(1-メチル-1H-1,2,3,4-テトラゾール-5-イル)スルファニル]メチル}-8-オキソ-5-チア-1-アザビシクロ[4.2.0]オクタ-2-エン-2-カルボン酸
- CPM【セフピラミド】